Sign In
Buy ANNX
$5.39
+0.130 (+2.47%)
At Close: Jun 03, 2026
Insider Selling: Annexon (NASDAQ:ANNX) Insider Sells $26,979.00 in Stock
05:36am, Monday, 23'rd Feb 2026
Annexon, Inc. (NASDAQ: ANNX - Get Free Report) insider Jamie Dananberg sold 5,290 shares of Annexon stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $
Annexon (NASDAQ:ANNX) EVP Sells $26,979.00 in Stock
05:36am, Monday, 23'rd Feb 2026
Annexon, Inc. (NASDAQ: ANNX - Get Free Report) EVP Dean Richard Artis sold 5,290 shares of the firm's stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $5.1
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
08:00am, Tuesday, 17'th Feb 2026
BRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammat
Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases
02:08am, Saturday, 24'th Jan 2026
Annexon offers high-risk, high-reward potential with its C1q-targeted pipeline, led by tanruprubart for GBS and vonaprument for geographic atrophy. Tanruprubart's Phase III results are promising, but
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
05:05pm, Friday, 16'th Jan 2026
BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammat
Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:06pm, Wednesday, 14'th Jan 2026
Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome ( GBS); BLA Submission with U.S./European Data Planned in 2026
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
08:00am, Thursday, 08'th Jan 2026
Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Wednesday, 07'th Jan 2026
BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammat
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
07:31pm, Tuesday, 16'th Dec 2025
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation acros
Pre-Market Stock Futures: The futures are trading higher this morning. Sellers regained the upper hand on Monday, starting the final trading month of 2025 on the downside after a blazing Thanksgiving-
Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy
05:23pm, Thursday, 20'th Nov 2025
Annexon Inc. (ANNX) is still a "Buy" in my view, driven by progress in its c1q inhibitor pipeline for rare diseases. ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned
BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation acros
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
10:55pm, Wednesday, 12'th Nov 2025
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation acros
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:12pm, Wednesday, 12'th Nov 2025
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing
